期刊文献+

荧光定量逆转录聚合酶链反应在前列腺特异性抗原基因检测中的应用价值 被引量:12

The measurement of prostate specific antigen mRNA in peripheral blood of prostate carcinoma by fluorescence quantitative reverse transcriptase polymerase chain reaction
原文传递
导出
摘要 目的 利用Taqman技术 ,建立荧光定量逆转录聚合酶链反应 (FQ RT PCR)技术 ,对前列腺癌病人外周血中前列腺特异性抗原基因 (PSAmRNA)进行定量检测。方法 在PSA基因的外显子 2和 3之间设计一对引物和一条Taqman探针 ;优化反应体系的条件 ,以不同LNCaP细胞含量为标准品和其循环阈值 (Ct值 )制作标准曲线 ,检测外周血中PSAmRNA含量 ;对本方法进行方法学评价及初步临床应用评价。结果 成功建立了FQ RT PCR检测PSAmRNA技术 ,本方法最低检测限为每毫升全血 5个LNCap细胞 ,线性范围为 5~ 1 0 8细胞 /ml,批内和批间变异系数分别为 9 5 %~1 4 3%和 1 5 2 %~ 2 0 1 % ,扩增产物克隆和测序分析显示本扩增片段为PSAmRNA序列的特异性片段。初步临床研究显示 ,1 0例经ECT ,检查证实骨转移的前列腺癌患者的外周血均检到PSAmRNA ,其含量变化为 8~ 1 0 4细胞 /ml,健康男性、女性各 5名外周血中PSAmRNA含量均小于本法最低检测限。结论 荧光定量逆转录聚合酶链反应检测PSAmRNA具有灵敏、特异、简便、结果数据化等特点 ,该方法可为前列腺癌微转移诊断、预后判断、指导治疗等奠定良好基础 。 Objective To develop fluorescence quantitative reverse transcriptase polymerase chain reaction(FQ RT PCR) for the measurement of prostate specific antigen(PSA) mRNA in peripheral blood of prostate carcinoma using the Taqman detection system Methods A pair of primers were designed to amplify a fragment of 145 bp between exon2 and exon3, A TaqMan probe modified with 6 Fam at 5' end and Tamra at its 3' end was designed, then, the detection system was developed The PCR product was cloned and sequenced with Beckman CEQ8000; Blood samples were collected from 10 patients with prostate carcinoma and from 5 female and male health controls respectively, the circulating prostate derived cells were isolated by the density gradient separation and PSAmRNA was measured Results The quantitative assay was developed using an external standard reference curve generated from the human prostate cell line LNCap, The assay's minimum limit was 5 cells/ml, the linear range was from 5 to 10 8cells/ml, the CV value is 9 5%~14 3% and 15 2%~20 1% respectively in intra and inter assay, the PCR product was specific for PSAmRNA sequence, PSAmRNA was detected from 8~10 4 cells/ml in patients with prostate carcinoma and not detected in healthy controls Conclusions The fluorescence quantitative reverse transcriptase polymerase chain reaction for the measurement of PSAmRNA was sensitive, specific and reliable procedure Circulating PSAmRNA is a promising marker for the detection and follow up of these patients
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2004年第3期148-151,共4页 Chinese Journal of Laboratory Medicine
基金 浙江省自然科学基金资助项目 (SZJ0 2 0 0 3 )
关键词 荧光定量逆转录聚合酶链反应 前列腺 特异性抗原 基因 检测 Prostate Genes Polymerase chain reaction
  • 相关文献

参考文献2

二级参考文献15

  • 1Guo YL. Benign prostate hyperplasia and prostate carcinoma [M]. 2nded. Bejing: Renmin Weishen Chubanshe (Bejing: People Medical Publishing Company), 1998: 131-138.
  • 2Chang SS, Gaudin PB, Reuter VE, Heston WD. Prostate-specific membrane antigen: Present and future applications [J]. Urology, 2000;55:622-629.
  • 3Bostwick CG, Pacelli A, Blutell. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases [J]. Cancer, 1998;82:2256-2259.
  • 4Murphy GP, Su S, Jarisch J, Kenny GM. Serum levels of PSMA [J]. Prostate, 2000;42(4):318-319.
  • 5Hara N, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tomita Y. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: Value for the Staging of Prostate Cancer [J]. Clin Cancer Res, 2002;8(6):1794-1799.
  • 6Llanes L, Ferruelo A, Paez A, Gomez JM, Moreno A, Berenguer A. The clinical utility of the prostate specific membrane antigen reverse-transcription/polymerase chain reaction to detect circulating prostate cells: An analysis in healthy men and women [J]. BJU Int, 2002;89(9):882-885.
  • 7Sourla A, Lembessis P, Mitsiades C, Dimopoulos T, Skouteris M, Metsinis M, Ntounis A, Ioannidis A, Katsoulis A, Kyragiannis V, Lambou T, Tsintavis A, Koutsilieris M. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients [J]. Anticancer Res, 2001;21(5):3565-3570.
  • 8Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma [J]. Urology, 2001;57(6):1179-1183.
  • 9Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells [J]. Prostate, 2000;45(4):350-354.
  • 10Tino WT, Huber MJ, Lake TP, Greene TG, Murphy GP, Holmes EH. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA) [J]. Hybridoma, 2000; 19(3):249-257.

共引文献5

同被引文献98

  • 1陈占国,陶志华,陈晓东.前列腺癌特异性基因DD3^(PCA3)的研究进展[J].国际检验医学杂志,2004,26(5):435-438. 被引量:3
  • 2那彦群,李鸣.重视前列腺癌诊治规范化研究[J].中华医学杂志,2005,85(45):3169-3169. 被引量:21
  • 3山刚志,金杰,郭应禄.不同前列腺穿刺活检方案检出前列腺癌的比较[J].中华泌尿外科杂志,2006,27(1):40-42. 被引量:24
  • 4毛晓露,陶志华,徐伟,陈晓东,陈占国,翁志梁,胡元平,吴秀玲,张筱骅,谢辉,王瓯晨,宋其同,李澄棣,余凯远.DD3和PSA基因在前列腺癌组织中的定量表达分析[J].中华泌尿外科杂志,2006,27(9):624-627. 被引量:6
  • 5叶定伟,李长岭.前列腺癌发病趋势的回顾和展望[J].中国癌症杂志,2007,17(3):177-180. 被引量:119
  • 6Amling C L, Blute M L, Bergstralh E J, et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued risk of biochemical failure after 5 years [ J ]. J Uro1,2000,164 ( 1 ) : 101-105.
  • 7Han M, Partin A W, Piantadosi S, et al.Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer[ J]. J Urol,2001,166(2) :416-419.
  • 8Hull G W, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients [ J]. J Urol, 2002, 167 (2) : 528 -534.
  • 9Pfitzenmaier J, Ellis W J, Hawley S,et al. The detection and isolation of viable prostate- specific antigen positive epithelial cens by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer[ J]. Urol Onco1,2007,25 (3) :214-220.
  • 10Chang S S, Reuter V E, Heston W D, et al. Comparison of anti - prostate - specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma [ J ]. Urology, 2001,57 (6) :1179-1183.

引证文献12

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部